Navigation Links
Viral Genetics Information Now Available Through OTCIQ.com and Pink Sheets Website
Date:7/8/2009

>http://www.pinksheets.com/content/doc/ps/Disclosure/Guidelines/2.pdf. The guidelines are intended to substantially follow the reporting requirements of registrants under Section 12 of the Securities Exchange Act administered by the SEC, although the requirements are voluntary when an issuer is not actually registered with the SEC.

Viral Genetics is now completing an Initial Disclosure Filing which will include un-audited financial statements from the period October 1, 2007 until the most recent quarter-end, as well as general company information, plan of operations, information about share issuances and capital structure, and other updates. In the interim, the company will make ongoing Current Reports under the OTCIQ system.

About Viral Genetics, Inc.:

Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV, AIDS and other autoimmune diseases using its thymus nuclear protein compound (TNP). The Company recently licensed technology developed by M. Karen Newell, PhD from the University of Colorado, that appears to explain TNP and provide a means to optimize therapies based on TNP for future clinical trials. Viral Genetics believes that its investigational HIV/AIDS drug based on TNP, called VGV-1, represents a unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment. As a type of immune-based therapy, VGV-1 focuses on boosting the immune system to allow the body to fight HIV more efficiently. VGV-1 has been studied in five human clinical trials for the treatment of HIV/AIDS. Online at www.viralgenetics.com

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:'/>"/>

SOURCE Viral Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
2. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
3. Companys Partner Completes Trial Production of a New Antiviral Medicine
4. Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million
5. SAFC Pharma to Increase Viral Product Manufacturing Capacity
6. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
7. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
8. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
9. World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic
10. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
11. Researchers decode viral process that prepares cells for HIV infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation ... Medtronic, Inc. (NYSE: MDT ) has ... Food and Drug Administration (FDA) for the use ... infusion system (including a newly developed catheter) for ... Injection delivered intravenously to patients with pulmonary arterial ...
(Date:12/24/2014)... 23, 2014 GMO corn cases filed ... Syngenta, are in the process of being consolidated in ... case is In Re: Syngenta AG MIR 162 Corn ... for the District of Kansas. , Management of the ... over to U.S. District Judge John W. Lungstrum.* , ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... on methyl mercaptan such as its definition, ... also presents product specification, manufacturing process, and ... regions, technology and applications. The analysis also ... survey, marketing channels, industry development trend and ...
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... over 60% of evaluable patients -, SEOUL, South ... today reported interim data from an ongoing phase 2 ... cell,lung cancer (NSCLC). This open-label phase 2 trial is ... NSCLC who have adenocarcinoma,histology and meet one of the ...
... Computing researchers at Houston,s Rice University and ... today announced the formation of a $2.6-million Institute ... valued at 4 million Singapore dollars, aims to ... microchips -- special-purpose computer chips that power everything ...
... Beckman Coulter,Inc. (NYSE: BEC ), a ... automate, and innovate complex biomedical testing,announced today that ... will present at the 2007 Bear Stearns Healthcare,Conference ... (EDT). (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ) The ...
Cached Biology Technology:Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer 2Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer 3Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer 4Rice, Nanyang Tech collaborate on sustainable nanoelectronics 2Rice, Nanyang Tech collaborate on sustainable nanoelectronics 3Beckman Coulter to Present at the Bear Stearns Healthcare Conference 2
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
(Date:12/10/2014)... , December 9, 2014 ... ITN,s BCARD Platform   ... enterprise meeting scheduling solutions for business-to-business (B2B) events, ... world leader in mobile near-field communication (NFC), Bluetooth ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... by University of Toronto Scarborough researchers gives the best ... severe mental illness called Borderline Personality Disorder (BPD), and ... work shows that brain regions that process negative emotions ... with BPD, while brain regions that would normally help ...
... since the early 1960s have fueled a sharp increase in ... consumed by the average person over the course of a ... McGill University. Between 1961 and 2007, rising meat consumption ... world,s per capita "phosphorus footprint," the researchers conclude in a ...
... organisms. They are still present today in oceans and ... and evolving into multicellular forms, they played a key ... This has, now, been demonstrated by a team of ... from the University of Zurich. According to their studies, ...
Cached Biology News:New insights into the 'borderline personality' brain 2Dietary shifts driving up phosphorus use 2Pediatric coding top tips and pediatric CPT changes 2013 2
Request Info...
Request Info...
CoverWell imaging chamber gasket with adhesive, one chamber, 20 mm diameter, 1.0 mm deep *set of 40* Cell Biology Imaging Tools and Accessories Microscope Slide Accessories...
Request Info...
Biology Products: